Last reviewed · How we verify
ABT-450
ABT-450 is a protease inhibitor that works by blocking the replication of the hepatitis C virus.
ABT-450 is a protease inhibitor that works by blocking the replication of the hepatitis C virus. Used for Chronic hepatitis C virus (HCV) infection, HCV genotype 1 infection.
At a glance
| Generic name | ABT-450 |
|---|---|
| Also known as | paritaprevir |
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | protease inhibitor |
| Target | HCV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
ABT-450 is a potent inhibitor of the HCV protease, which is essential for the replication of the hepatitis C virus. By blocking this enzyme, ABT-450 prevents the virus from producing new viral particles, ultimately leading to a reduction in viral load.
Approved indications
- Chronic hepatitis C virus (HCV) infection
- HCV genotype 1 infection
Common side effects
- Fatigue
- Headache
- Nausea
Key clinical trials
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment (PHASE4)
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection (PHASE4)
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (PHASE3)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-450 CI brief — competitive landscape report
- ABT-450 updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI